Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Oncology

    Current Location

    Search
    Oncology
    Show Map
    Map View
    Your Location

    Popular Searches

    By Condition

    Depression Clinical Trials

    Anxiety Clinical Trials

    Schizophrenia Clinical Trials

    ADHD Clinical Trials

    Bipolar Disorder Clinical Trials

    Multiple Sclerosis Clinical Trials

    Autism Clinical Trials

    Treatment Resistant Depression Clinical Trials

    Borderline Personality Disorder Clinical Trials

    Social Anxiety Disorder Clinical Trials

    Parkinson's Disease Clinical Trials

    Alzheimer's Disease Clinical Trials

    By Location

    Clinical Trials in California

    Clinical Trials in Florida

    Clinical Trials in Texas

    Clinical Trials in New York

    Clinical Trials in Ohio

    Clinical Trials in Illinois

    Clinical Trials in Pennsylvania

    Clinical Trials in Michigan

    Clinical Trials in North Carolina

    Clinical Trials in Massachusetts

    Clinical Trials in Missouri

    Clinical Trials in Minnesota

    Other People Viewed

    By Subject

    Top Asthma Clinical Trials

    Top Anxiety Disorder Clinical Trials

    Top Thyroid Cancer Clinical Trials

    Top Cervical Cancer Clinical Trials

    Top Craniopharyngioma Clinical Trials

    Top Colitis Clinical Trials

    Top Retinoblastoma Clinical Trials

    Top Addiction Clinical Trials

    Top Menopause Clinical Trials

    Top Myopia Clinical Trials

    Top Narcolepsy Clinical Trials

    Top Hydrocephalus Clinical Trials

    By Trial

    Online Psychotherapy for Anxiety and Depression in Cancer Patients

    System-level Tobacco Treatment Intervention for Smoking Cessation

    Alpha-Stim AID + Life Coaching for Mental Health Disorders

    Nudge for Ovarian Cancer

    ReSPECT for Cancer

    SPOT-ON for Shortness of Breath in Cancer Patients

    Early Radiation Therapy for Cancer

    Survivorship Care Planning + Telehealth Education for Cancer

    Educational Media Interventions for Cancer

    Dabrafenib + Trametinib Access for Cancer

    Comprehensive Care Model for Cancer Survivors

    CONNECT Platform for Cancer Care

    Related Searches

    Top Psoriasis Clinical Trials

    Top Systemic-lupus-erythematosus Clinical Trials

    Functional Electrical Stimulation for Post-Stroke Weakness

    Top Type-2-diabetes Clinical Trials

    ATI-V Program for Preventing Adolescent Vaping

    Accelerated Theta Burst Stimulation for Suicidal Thoughts

    Combination Immunotherapy for Cancer

    Pelacarsen for Cardiovascular Disease

    Ketogenic Diet for Schizophrenia

    NPT 2042 for Epilepsy

    Saline and Diuretic for High Blood Pressure

    Electronic Monitoring Device for HIV

    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      91 Oncology Trials Near You

      Power is an online platform that helps thousands of Oncology patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      MRI vs. Ultrasound Screening for Liver Cancer

      Cleveland, Ohio
      The study is a randomized trial of two different screening methods for early detection of liver cancer in patients with cirrhosis of the liver. The goal of PREMIUM is to compare an abbreviated version of the diagnostic gold standard for HCC (aMRI) +AFP to the standard-of-care screening (US+AFP) in patients at high risk of developing HCC. The investigators hypothesize that HCC will be detected at earlier stages, allowing for more curative treatments and resulting in a reduction in HCC-related mortality.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:HCC, Organ Transplant, Advanced Liver Dysfunction, GFR <30, Others

      4700 Participants Needed

      SRF388 + Pembrolizumab for Cancer

      Cleveland, Ohio
      This trial tests CHS-388, a protein that blocks IL-27, in patients with severe cancers like kidney, liver, and lung cancer. The goal is to see if it helps the immune system fight cancer better.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Uncontrolled Diabetes, Unstable Cardiac, Others
      Must Be Taking:VEGF-targeted Agents

      260 Participants Needed

      TOL2506 + Standard Therapy for Breast Cancer

      Lexington, Kentucky
      TOL2506A (OVELIA) is a Phase 3, single arm, open-label study evaluating the effectiveness of TOL2506 in suppressing ovarian function in premenopausal women with HR+, HER2-negative breast cancer and men with HR+ breast cancer. The TOL2506A-EXT study described here is a safety extension study to assess and collect long-term data on the ongoing safety and tolerability of TOL2506 in combination with tamoxifen or an AI for up to 4 years.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Phase 3
      Age:18 - 51

      Key Eligibility Criteria

      Disqualifiers:Low BMI, Hepatic Impairment, Others
      Must Be Taking:Endocrine Therapy, GnRH Agonist

      250 Participants Needed

      Hope Intervention for Advanced Lung Cancer

      Lexington, Kentucky
      This study will compare the effects of a brief supportive intervention, called Pathways, against enhanced usual care on the mental health and quality of life of people undergoing treatment for advanced lung cancer. Patients will complete baseline survey measures and be randomized to intervention. Survey measures will be collected again mid-intervention, post-intervention and at 6- and 12-week follow-up, with analyses focused on changes pre- to post-intervention.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Unstable Brain Metastases, Dementia, Psychotic Disorder, Others

      234 Participants Needed

      Survivorship Care for Lung Cancer

      Lexington, Kentucky
      The overarching goal of the Kentucky LEADS Collaborative Lung Cancer Survivorship Care program is to reduce the burden of lung cancer by offering an innovative survivorship care approach that improves lung cancer quality of life, overcomes lung cancer stigma, and helps survivors engage with care. The project involves a two-group parallel randomized clinical trial comparing the impact of the Kentucky LEADS Collaborative Lung Cancer Survivorship Care program (KLCLCSC) among lung cancer survivors (N=300) against an enhanced usual care condition (bibliotherapy+assessment) on quality of life outcomes.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Psychiatric Disturbance, Substance Abuse, Others

      300 Participants Needed

      FOCUS ON US Program for Cancer Patients

      Detroit, Michigan
      Our aim for this study is to assess the feasibility and acceptability and explore potential outcomes of the adapted FOCUS On Us intervention in a two-arm pilot trial. The investigators will randomize 80 sexual and/or gender minority (SGM; e.g., lesbian, gay, bisexual, transgender, queer, etc.) cancer patients and their ≥80 informal caregivers (total N≥160) to either FOCUS On Us (adapted from the evidence-based FOCUS program) or a waitlist control.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      160 Participants Needed

      Spinal Cord Stimulation for Stroke Recovery

      Pittsburgh, Pennsylvania
      The goal of this study is to verify whether electrical stimulation of the cervical spinal cord can activate muscles of the arm and hand in people with hemiplegia following stroke. Participants will undergo a surgical procedure to implant a system which provides epidural electrical stimulation (EES) of the cervical spinal cord. Researchers will quantify the ability of EES to recruit arm and hand muscles and produce distinct kinematic movements. The implant will be removed after less than 30 days. Results of this study will provide the foundation for future studies evaluating the efficacy of a minimally-invasive neuro-technology that can be used in clinical neurorehabilitation programs to restore upper limb motor function in people with subcortical strokes, thereby increasing independence and quality of life.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:21 - 70

      Key Eligibility Criteria

      Disqualifiers:Neurological Conditions, Cancer, Severe Cardiac, Others
      Must Not Be Taking:Anticoagulants, Anti-spasticity, Anti-epileptics

      15 Participants Needed

      NST-628 for Cancer

      Pittsburgh, Pennsylvania
      This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment options.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Retinal Pathology, Cardiovascular Risk, ILD, Others
      Must Not Be Taking:MEK Inhibitors, BRAF Inhibitors

      230 Participants Needed

      E-602 + Cemiplimab for Cancer

      Pittsburgh, Pennsylvania
      This is a Phase 1/2, first-in-human, open-label, dose escalation and dose-expansion study of E-602, administered alone and in combination with cemiplimab.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      273 Participants Needed

      Sotorasib Combo vs Pembrolizumab Combo for Advanced Lung Cancer

      Pittsburgh, Pennsylvania
      This trial is testing two different drug combinations with chemotherapy to see which helps cancer patients live longer without their disease getting worse. One combination includes sotorasib, which targets cancer mutations, and the other includes pembrolizumab, which helps the immune system fight cancer. Pembrolizumab has been shown to improve overall survival in various cancers when combined with chemotherapy.
      No Placebo Group
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Mixed Histology NSCLC, Brain Metastases, GI Tract Disease, Myocardial Infarction, Others

      750 Participants Needed

      AMG 193 for Non-Small Cell Lung Cancer

      Ann Arbor, Michigan
      The main objective of the study is to characterize safety and efficacy of 2 dose levels of AMG 193 by investigator, and to evaluate AMG 193 monotherapy efficacy by Blinded Independent Central Review (BICR).
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:EGFR, ALK, ROS1, Others

      200 Participants Needed

      AMG 193 + IDE397 for Solid Cancers

      Ann Arbor, Michigan
      This trial tests the safety and best dose of two drugs, AMG 193 and IDE397, in adults with advanced cancers missing the MTAP gene, especially lung cancer. The goal is to see if this combination can effectively fight these cancers.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Brain Metastases, Bowel Obstruction, Others
      Must Not Be Taking:CYP3A4/5 Inducers, Inhibitors

      53 Participants Needed

      RP3 + Nivolumab for Solid Tumors

      Pittsburgh, Pennsylvania
      This trial is testing a new treatment called RP3, which is a modified virus designed to attack cancer cells and help the immune system fight cancer. It targets adult patients with advanced solid tumors who need new treatment options. The virus works by directly killing cancer cells and boosting the body's immune response against the cancer. Reovirus is a double-stranded RNA virus that has shown promise in targeting cancer cells.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Viral Infections, Pneumonitis, Autoimmune, Others
      Must Not Be Taking:Systemic Antivirals, Botanical Preparations

      123 Participants Needed

      BBO-10203 + Trastuzumab for Breast Cancer

      Indianapolis, Indiana
      First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with other anti-cancer agents in patients with advanced solid tumors.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Untreated Brain Metastases, BRAFV600E, Others
      Must Be Taking:Anti-HER2 Therapy

      392 Participants Needed

      5-Aminolevulinic Acid for Urothelial Carcinoma

      Detroit, Michigan
      This study is evaluating whether a medication called 5-aminolevulinic acid (5-ALA), approved by the FDA for use in brain surgery, can help improve the visibility of upper tract urothelial tumors during surgery. Patients undergoing ureteroscopic tumor resection will receive 5-ALA prior to surgery, and surgeons will use special blue light to help identify abnormal tissue that might not be seen under standard white light. The goal is to assess whether this technique can enhance tumor detection and removal.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Porphyria, Pregnancy, Liver Issues, Others

      10 Participants Needed

      Lifestyle Intervention for Blood Cancer

      Pittsburgh, Pennsylvania
      Background. This study aims to evaluate the effectiveness of a telehealth-mediated lifestyle intervention program tailored for veterans with blood cancer, focusing on improving health-related quality of life, mental health, and pain outcomes. The hypothesis posits that the telehealth-delivered program will lead to significant improvements in these areas, specifically targeting veterans undergoing treatment or in post-treatment phases. Objective. Recognizing the unique experiences of veterans, especially those in rural or underserved regions, this study seeks to provide insights into the feasibility and impact of telehealth-based lifestyle interventions for this distinct population. Methods. The pilot trial will enroll 30 veterans from the H. John Heinz III VA. Participants will complete baseline web-based surveys assessing demographics, occupational performance, and telehealth preparedness. The intervention comprises progressive resistance and aerobic exercises delivered via telehealth by a health coach, starting with a live supervised session followed by regular remote sessions. Each participant will engage in exercise sessions coordinated through the Veteran's Video Connect (VVC) application, with ongoing communication facilitated via email. This setup allows the health coach to adjust exercise intensity based on real-time symptom feedback. To address potential technology literacy biases, the VVCMatch assessment will categorize veterans as "technology prepared" or in need of additional education. Those requiring support will receive guidance on using the VVC app before starting the intervention. Additionally, participants will receive dietary consultations from the Leukemia and Lymphoma Society, independent of the research team. Outcome measures include assessments of symptoms, fatigue, function, mental health, and pain, along with evaluations of the intervention's usability through surveys on perceived usefulness and ease of use. These assessments aim to detect meaningful changes and ensure the intervention's effectiveness and acceptability among veterans.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Significant Disabilities, No Smart Device, Pregnant

      30 Participants Needed

      BAY 2416964 + Pembrolizumab for Cancer

      Detroit, Michigan
      This trial tests a new drug, BAY 2416964, combined with pembrolizumab to treat advanced cancers like head and neck, lung, and bladder cancer. BAY 2416964 helps the immune system fight cancer by blocking a protein that hinders immune cells. The study aims to find the safest and most effective dose of this combination.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      47 Participants Needed

      Tarlatamab Combo for Small Cell Lung Cancer

      Detroit, Michigan
      This trial is testing a new drug called tarlatamab combined with treatments that help the immune system fight cancer, and sometimes with chemotherapy. It targets cancer patients who need new treatment options. Tarlatamab attacks cancer cells directly, while other treatments boost the immune response or kill cancer cells.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Other Malignancy, Brain Metastases, Others
      Must Not Be Taking:Immunosuppressants, Steroids

      184 Participants Needed

      SQ3370 for Cancer

      Detroit, Michigan
      The purpose of this study is to evaluate the safety, tolerability, and preliminary activity of SQ3370 in patients with advanced solid tumors.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Congestive Heart Failure, CNS Metastases, Others
      Must Not Be Taking:Anthracyclines, Trastuzumab

      145 Participants Needed

      Sotorasib + Panitumumab + FOLFIRI for Colorectal Cancer

      Detroit, Michigan
      The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb.
      No Placebo Group
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Brain Metastases, Leptomeningeal Disease, Others

      450 Participants Needed

      Why Other Patients Applied

      "My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

      HZ
      Arthritis PatientAge: 78

      "As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

      IZ
      Healthy Volunteer PatientAge: 38

      "I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

      AG
      Paralysis PatientAge: 50

      "I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

      ZS
      Depression PatientAge: 51

      "I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

      ID
      Pancreatic Cancer PatientAge: 40
      Match to a Oncology Trial

      MEDI5752 for Solid Cancers

      Detroit, Michigan
      This trial is testing a new drug called MEDI5752 along with common chemotherapy drugs in adults with advanced cancer. The goal is to see if MEDI5752 can help fight cancer on its own or when combined with chemotherapy.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Autoimmune Disorders, Organ Transplant, Others
      Must Not Be Taking:Immunosuppressants, Live Vaccines

      401 Participants Needed

      mRNA-4359 + Pembrolizumab for Solid Cancers

      Detroit, Michigan
      This trial aims to test the safety of mRNA-4359 alone and with pembrolizumab in likely cancer patients. mRNA-4359 helps cells make a helpful protein, and pembrolizumab boosts the immune system's ability to fight cancer.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2
      Age:12+

      Key Eligibility Criteria

      Disqualifiers:CNS Tumors, Active Infection, Pregnancy, Others
      Must Not Be Taking:Chemotherapy, Immunotherapy, Hormonal Therapy, Others

      361 Participants Needed

      CHS-114 + Toripalimab for Cancer

      Pittsburgh, Pennsylvania
      The main purpose of this study is to evaluate the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s) in participants with advanced or metastatic solid tumors.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Prior Malignancy, CNS Metastases, Others
      Must Not Be Taking:Corticosteroids, CCR8 Antibodies

      154 Participants Needed

      Symptom Self-Management for Lung Cancer

      Ann Arbor, Michigan
      The use of immune checkpoint inhibitors (ICIs), alone or in combination with other cancer treatments is increasing dramatically with immune-related adverse events (irAEs) common (90%) during ICI treatment. Most irAEs are symptomatic and symptom self-management with timely reporting of moderate or severe symptoms to health care providers (HCPs) may reduce irAE severity by early recognition and management, resulting in fewer treatment interruptions and unscheduled health services.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Regular Behavioral Counseling
      Must Be Taking:Immune Checkpoint Inhibitors

      400 Participants Needed

      SLC-3010 + Gemcitabine for Solid Cancers

      Detroit, Michigan
      This is a Phase 1/2, open-label, multicenter, dose escalation and expansion study, evaluating the safety, tolerability, pharmacokinetic, preliminary anti-tumor activity, and effects on pharmacodynamic markers following administration of SLC-3010 as monotherapy and in combination with gemcitabine, in patients with various advanced solid tumors.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Active Infection, Cardiovascular Disease, Autoimmune Disease, Others
      Must Not Be Taking:Immunosuppressants, Corticosteroids

      420 Participants Needed

      Atezolizumab + Bevacizumab +/− SRF388 for Liver Cancer

      Detroit, Michigan
      This trial tests SRF388 with atezolizumab and bevacizumab in patients with advanced liver cancer. The treatment aims to enhance immune response and block blood supply to tumors. Atezolizumab and bevacizumab have become the standard of care for advanced hepatocellular carcinoma, replacing sorafenib which was the standard for over ten years.
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Autoimmune, HIV, Hepatitis, Others
      Must Not Be Taking:Steroids, Immunosuppressants

      134 Participants Needed

      Nemvaleukin Alfa for Melanoma

      Louisville, Kentucky
      This study observes the antitumor activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Uveal Melanoma, Pregnancy, CNS Metastases, Others
      Must Be Taking:Anti-PD-L1 Therapy

      180 Participants Needed

      Topical Cream for Peripheral Neuropathy

      Goshen, Indiana
      This trial tests a skin cream called WST-057 on patients receiving chemotherapy with Carboplatin and Paclitaxel. The cream is applied to the skin to help manage side effects from the chemotherapy. Carboplatin and Paclitaxel are frequently used together in treatments for various cancers, including gynecological malignancies.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Peripheral Neuropathy, Severe Paclitaxel Hypersensitivity, Macrovascular Disease, Others
      Must Be Taking:Carboplatin, Paclitaxel

      60 Participants Needed

      Intratumoral IP-001 Injection for Solid Cancers

      Louisville, Kentucky
      The goal of this clinical trial is to determine the safety and efficacy of IP-001 for intratumoral injection administration following thermal ablation of a solid tumor.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      44 Participants Needed

      INV-1120 + Pembrolizumab for Advanced Cancer

      Lafayette, Indiana
      Phase 1, open-label dose-escalation study to determine the MTD of INV-1120 and RP2D, and to assess the DLT of INV-1120 as a single agent or in the combination with pembrolizumab. The safety, tolerability, and PK of INV-1120 as a single agent or in the combination with pembrolizumab will be assessed in adult patients with advanced solid tumors.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Cancer, Autoimmune, Infections, Cardiac, Others
      Must Not Be Taking:H2 Blockers, Proton Pump Inhibitors

      78 Participants Needed

      1234

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Oncology clinical trials pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Oncology clinical trials work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Oncology trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Oncology is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Oncology medical study?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Oncology clinical trials?

      Most recently, we added WISH Program for Cancer Treatment, Comfort-Enhancing Techniques for Bladder Cancer and Darovasertib for Eye Cancer to the Power online platform.